Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis.
Conferences
Azad, A; Iguchi, T; Alekseev, B; Shore, ND; Sugg, J; Haas, GP; Wozniak, M; O'Brien, T; Laird, D; Stenzl, A; Armstrong, AJ
Published in: JOURNAL OF CLINICAL ONCOLOGY
June 1, 2022
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
June 1, 2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Azad, A., Iguchi, T., Alekseev, B., Shore, N. D., Sugg, J., Haas, G. P., … Armstrong, A. J. (2022). Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).
Azad, Arun, Taro Iguchi, Boris Alekseev, Neal D. Shore, Jennifer Sugg, Gabriel P. Haas, Michele Wozniak, et al. “Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.
Azad A, Iguchi T, Alekseev B, Shore ND, Sugg J, Haas GP, et al. Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis. In: JOURNAL OF CLINICAL ONCOLOGY. 2022.
Azad, Arun, et al. “Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis.” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.
Azad A, Iguchi T, Alekseev B, Shore ND, Sugg J, Haas GP, Wozniak M, O’Brien T, Laird D, Stenzl A, Armstrong AJ. Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis. JOURNAL OF CLINICAL ONCOLOGY. 2022.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
June 1, 2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis